Ken Kato

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 97

Top Topics

Locally Advanced

Squamous Cell Carcinoma

Top Venues

Esophagus : official journal of the Japan Esophageal Society

Future oncology (London, England)

Japanese journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Wasat Mansoor, Seongjung Joo, Josephine M Norquist, Ken Kato, Jong-Mu Sun, Manish A Shah, Peter Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean-Philippe Metges, Zhigang Li, Sung-Bae Kim, Byoung Chol Cho, Patrapim Sunpaweravong, Maria Alsina Maqueda, Eray Goekkurt, Shailaja Suryawanshi, Sukrut Shah, Lin Shen
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer. The oncologist (2024)
Jong-Mu Sun, Antoine Adenis, Peter C Enzinger, Manish A Shah, Ken Kato, Jaafar Bennouna, Toshihiko Doi, Natalyn Nicole Hawk, Li Yu, Sukrut Shah, Pooja Bhagia, Lin Shen
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future oncology (London, England) (2024)
Toshiharu Hirose, Shun Yamamoto, Yoshitaka Honma, Kazuki Yokoyama, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Koshiro Ishiyama, Junya Oguma, Hiroyuki Daiko, Shin Maeda, Ken Kato
Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma. Esophagus : official journal of the Japan Esophageal Society 21 (3) (2024)
Hiroki Hara, Taroh Satoh, Takashi Kojima, Takahiro Tsushima, Yu Sunakawa, Morihito Okada, Ningning Ding, Hongqian Wu, Liyun Li, Tian Yu, Gisoo Barnes, Ken Kato
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302. Esophagus : official journal of the Japan Esophageal Society 21 (2) (2024)
Kazumasa Yamamoto, Shun Yamamoto, Ken Kato
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation. Expert opinion on drug safety (2024)
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya-Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer A Ajani
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer medicine 13 (9) (2024)
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya-Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer A Ajani
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer medicine 13 (9) (2024)
Wasat Mansoor, Seongjung Joo, Josephine M Norquist, Ken Kato, Jong-Mu Sun, Manish A Shah, Peter Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean-Philippe Metges, Zhigang Li, Sung-Bae Kim, Byoung Chol Cho, Patrapim Sunpaweravong, Maria Alsina Maqueda, Eray Goekkurt, Shailaja Suryawanshi, Sukrut Shah, Lin Shen
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer. The oncologist (2024)
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya-Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer A Ajani
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer medicine 13 (9) (2024)
Hiroki Hara, Taroh Satoh, Takashi Kojima, Takahiro Tsushima, Yu Sunakawa, Morihito Okada, Ningning Ding, Hongqian Wu, Liyun Li, Tian Yu, Gisoo Barnes, Ken Kato
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302. Esophagus : official journal of the Japan Esophageal Society (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Hiroki Hara, Taroh Satoh, Takashi Kojima, Takahiro Tsushima, Yu Sunakawa, Morihito Okada, Ningning Ding, Hongqian Wu, Liyun Li, Tian Yu, Gisoo Barnes, Ken Kato
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302. Esophagus : official journal of the Japan Esophageal Society 21 (2) (2024)
Yoshiaki Nakamura, Hiroshi Ozaki, Makoto Ueno, Yoshito Komatsu, Satoshi Yuki, Taito Esaki, Hiroya Taniguchi, Yu Sunakawa, Kensei Yamaguchi, Ken Kato, Tadamichi Denda, Tomohiro Nishina, Naoki Takahashi, Taroh Satoh, Hisateru Yasui, Hironaga Satake, Eiji Oki, Takeshi Kato, Takashi Ohta, Nobuhisa Matsuhashi, Masahiro Goto, Naohiro Okano, Koushiro Ohtsubo, Kentaro Yamazaki, Riu Yamashita, Naoko Iida, Mihoko Yuasa, Hideaki Bando, Takayuki Yoshino
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. Nature medicine (2024)
Kotoe Oshima, Takahiro Tsushima, Yoshinori Ito, Ken Kato
Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma. Japanese journal of clinical oncology (2024)
Kazumasa Yamamoto, Shun Yamamoto, Ken Kato
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation. Expert opinion on drug safety (2024)
Kotoe Oshima, Takahiro Tsushima, Yoshinori Ito, Ken Kato
Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma. Japanese journal of clinical oncology 54 (4) (2024)
Takashi Uehara, Juntaro Matsuzaki, Hiroshi Yoshida, Yuto Ogawa, Junichiro Miura, Hitoshi Fujimiya, Yusuke Yamamoto, Junpei Kawauchi, Satoko Takizawa, Kan Yonemori, Hiromi Sakamoto, Ken Kato, Mitsuya Ishikawa, Takahiro Ochiya
Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer. Japanese journal of clinical oncology (2024)
Naoko Iida, Mitsuho Imai, Wataru Okamoto, Takeshi Kato, Taito Esaki, Ken Kato, Yoshito Komatsu, Satoshi Yuki, Toshiki Masuishi, Tomohiro Nishina, Hiromichi Ebi, Hiroya Taniguchi, Norio Nonomura, Yu Sunakawa, Manabu Shiozawa, Kentaro Yamazaki, Shogen Boku, Hideaki Bando, Yuichi Shiraishi, Maki Kobayashi, Hiroki Goto, Akihiro Sato, Satoshi Fujii, Takayuki Yoshino, Yoshiaki Nakamura
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Hiroki Hara, Taroh Satoh, Takashi Kojima, Takahiro Tsushima, Yu Sunakawa, Morihito Okada, Ningning Ding, Hongqian Wu, Liyun Li, Tian Yu, Gisoo Barnes, Ken Kato
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302. Esophagus : official journal of the Japan Esophageal Society 21 (2) (2024)
Kazumasa Yamamoto, Shun Yamamoto, Ken Kato
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation. Expert opinion on drug safety 23 (6) (2024)
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya-Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer A Ajani
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer medicine 13 (9) (2024)
Ken Kato, Takashi Kojima, Hiroki Hara, Akihito Tsuji, Hisateru Yasui, Kei Muro, Taroh Satoh, Takashi Ogata, Ryu Ishihara, Masahiro Goto, Hideo Baba, Tomohiro Nishina, ShiRong Han, Keiichi Iwakami, Naoyoshi Yatsuzuka, Toshihiko Doi
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study. Esophagus : official journal of the Japan Esophageal Society 21 (3) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Jong-Mu Sun, Antoine Adenis, Peter C Enzinger, Manish A Shah, Ken Kato, Jaafar Bennouna, Toshihiko Doi, Natalyn Nicole Hawk, Li Yu, Sukrut Shah, Pooja Bhagia, Lin Shen
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future oncology (London, England) (2024)
Toshiharu Hirose, Shun Yamamoto, Yoshitaka Honma, Kazuki Yokoyama, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Koshiro Ishiyama, Junya Oguma, Hiroyuki Daiko, Shin Maeda, Ken Kato
Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma. Esophagus : official journal of the Japan Esophageal Society 21 (3) (2024)
Ken Kato, Takashi Kojima, Hiroki Hara, Akihito Tsuji, Hisateru Yasui, Kei Muro, Taroh Satoh, Takashi Ogata, Ryu Ishihara, Masahiro Goto, Hideo Baba, Tomohiro Nishina, ShiRong Han, Keiichi Iwakami, Naoyoshi Yatsuzuka, Toshihiko Doi
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study. Esophagus : official journal of the Japan Esophageal Society 21 (3) (2024)
Ken Kato, Takashi Kojima, Hiroki Hara, Akihito Tsuji, Hisateru Yasui, Kei Muro, Taroh Satoh, Takashi Ogata, Ryu Ishihara, Masahiro Goto, Hideo Baba, Tomohiro Nishina, ShiRong Han, Keiichi Iwakami, Naoyoshi Yatsuzuka, Toshihiko Doi
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study. Esophagus : official journal of the Japan Esophageal Society (2024)
Kotoe Oshima, Takahiro Tsushima, Yoshinori Ito, Ken Kato
Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma. Japanese journal of clinical oncology 54 (4) (2024)
Ken Kato, Takashi Kojima, Hiroki Hara, Akihito Tsuji, Hisateru Yasui, Kei Muro, Taroh Satoh, Takashi Ogata, Ryu Ishihara, Masahiro Goto, Hideo Baba, Tomohiro Nishina, ShiRong Han, Keiichi Iwakami, Naoyoshi Yatsuzuka, Toshihiko Doi
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study. Esophagus : official journal of the Japan Esophageal Society 21 (3) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya-Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer A Ajani
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer medicine 13 (9) (2024)
Kazumasa Yamamoto, Shun Yamamoto, Ken Kato
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation. Expert opinion on drug safety 23 (6) (2024)
Hiroki Hara, Taroh Satoh, Takashi Kojima, Takahiro Tsushima, Yu Sunakawa, Morihito Okada, Ningning Ding, Hongqian Wu, Liyun Li, Tian Yu, Gisoo Barnes, Ken Kato
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302. Esophagus : official journal of the Japan Esophageal Society 21 (2) (2024)
Nozomu Ogura, Shun Yamamoto, Ken Kato
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma. Expert opinion on biological therapy (2024)
Nozomu Ogura, Shun Yamamoto, Ken Kato
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma. Expert opinion on biological therapy 24 (6) (2024)
Takashi Uehara, Juntaro Matsuzaki, Hiroshi Yoshida, Yuto Ogawa, Junichiro Miura, Hitoshi Fujimiya, Yusuke Yamamoto, Junpei Kawauchi, Satoko Takizawa, Kan Yonemori, Hiromi Sakamoto, Ken Kato, Mitsuya Ishikawa, Takahiro Ochiya
Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer. Japanese journal of clinical oncology 54 (8) (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Nozomu Ogura, Shun Yamamoto, Ken Kato
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma. Expert opinion on biological therapy 24 (6) (2024)
Ken Kato, Takashi Kojima, Hiroki Hara, Akihito Tsuji, Hisateru Yasui, Kei Muro, Taroh Satoh, Takashi Ogata, Ryu Ishihara, Masahiro Goto, Hideo Baba, Tomohiro Nishina, ShiRong Han, Keiichi Iwakami, Naoyoshi Yatsuzuka, Toshihiko Doi
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study. Esophagus : official journal of the Japan Esophageal Society 21 (3) (2024)
Toshiharu Hirose, Shun Yamamoto, Yoshitaka Honma, Kazuki Yokoyama, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Koshiro Ishiyama, Junya Oguma, Hiroyuki Daiko, Shin Maeda, Ken Kato
Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma. Esophagus : official journal of the Japan Esophageal Society 21 (3) (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Kazuhiro Shiraishi, Yuki Takeyasu, Shun Yamamoto, Kotoe Oshima, Hiroshi Imazeki, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Satoru Iwasa, Atsuo Takasima, Ken Kato
Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma. Esophagus : official journal of the Japan Esophageal Society (2024)
Toshiharu Hirose, Shun Yamamoto, Yoshitaka Honma, Kazuki Yokoyama, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Koshiro Ishiyama, Junya Oguma, Hiroyuki Daiko, Shin Maeda, Ken Kato
Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma. Esophagus : official journal of the Japan Esophageal Society (2024)
Hiroki Hara, Taroh Satoh, Takashi Kojima, Takahiro Tsushima, Yu Sunakawa, Morihito Okada, Ningning Ding, Hongqian Wu, Liyun Li, Tian Yu, Gisoo Barnes, Ken Kato
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302. Esophagus : official journal of the Japan Esophageal Society 21 (2) (2024)
Ryosuke Kita, Yoshitomo Yanagimoto, Hiroshi Imazeki, Eisuke Booka, Takahiro Tsushima, Junki Mizusawa, Keita Sasaki, Haruhiko Fukuda, Yukinori Kurokawa, Hiroya Takeuchi, Ken Kato, Yuko Kitagawa, Narikazu Boku, Takaki Yoshikawa, Masanori Terashima, null null
Protocol digest of a randomized controlled adaptive Phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). Japanese journal of clinical oncology (2023)
Toshiharu Hirose, Shun Yamamoto, Ken Kato
Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer. Therapeutic advances in gastroenterology 16 (2023)
Yuntae Kim, Shun Yamamoto, Ken Kato
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data. Cancer management and research 15 (2023)
Toshiharu Hirose, Shun Yamamoto, Ken Kato
Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer. Therapeutic advances in gastroenterology 16 (2023)
Go Ikeda, Jun Miyakoshi, Shun Yamamoto, Ken Kato
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. Future oncology (London, England) 20 (11) (2023)
Yoshiaki Nakamura, Riu Yamashita, Wataru Okamoto, Yoshito Komatsu, Satoshi Yuki, Makoto Ueno, Ken Kato, Hiroya Taniguchi, Yoshinori Kagawa, Tadamichi Denda, Hiroki Hara, Taito Esaki, Toshikazu Moriwaki, Yu Sunakawa, Eiji Oki, Fumio Nagashima, Tomohiro Nishina, Taroh Satoh, Hiasto Kawakami, Kensei Yamaguchi, Koushiro Ohtsubo, Takeshi Kato, Yosuke Horita, Akihito Tsuji, Hisateru Yasui, Masahiro Goto, Yasuo Hamamoto, Masashi Wakabayashi, Takashi Ikeno, Kohei Shitara, Hideaki Bando, Katsuya Tsuchihara, Izumi Miki, Hiroko Ichiki, Atsushi Ohtsu, Takayuki Yoshino
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program. JCO precision oncology 7 (2023)
Go Ikeda, Jun Miyakoshi, Shun Yamamoto, Ken Kato
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. Future oncology (London, England) (2023)
Yuntae Kim, Shun Yamamoto, Ken Kato
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data. Cancer management and research 15 (2023)
Koji Ando, Yoshiaki Nakamura, Hiroyuki Kitao, Mototsugu Shimokawa, Daisuke Kotani, Hideaki Bando, Tomohiro Nishina, Takanobu Yamada, Satoshi Yuki, Yukiya Narita, Hiroki Hara, Takashi Ohta, Taito Esaki, Yasuo Hamamoto, Ken Kato, Yoshiyuki Yamamoto, Keiko Minashi, Koushiro Ohtsubo, Naoki Izawa, Hiasto Kawakami, Takeshi Kato, Taroh Satoh, Naohiro Okano, Akihito Tsuji, Kentaro Yamazaki, Takayuki Yoshino, Yoshihiko Maehara, Eiji Oki
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study). British journal of cancer (2023)
Go Ikeda, Jun Miyakoshi, Shun Yamamoto, Ken Kato
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. Future oncology (London, England) 20 (11) (2023)
Morihito Okada, Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, Chueh-Chuan Yen, Yutaro Kubota, Sung-Bae Kim, Chih-Hung Hsu, Eva Holtved, Ioannis Xynos, Yasuhiro Matsumura, Akira Takazawa, Yuko Kitagawa
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). Clinical cancer research : an official journal of the American Association for Cancer Research 28 (15) (2022)
Yasuo Hamamoto, Kentaro Murakami, Ken Kato, Yuko Kitagawa
Management of elderly patients with esophageal squamous cell cancer. Japanese journal of clinical oncology 52 (8) (2022)
Takashi Kojima, Hiroki Hara, Akihito Tsuji, Hisateru Yasui, Kei Muro, Taroh Satoh, Takashi Ogata, Ryu Ishihara, Masahiro Goto, Hideo Baba, Tomohiro Nishina, Shirong Han, Tomoko Sakata, Naoyoshi Yatsuzuka, Toshihiko Doi, Ken Kato
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590. Esophagus : official journal of the Japan Esophageal Society 19 (4) (2022)
Kotoe Oshima, Ken Kato, Yoshinori Ito, Hiroyuki Daiko, Isao Nozaki, Satoru Nakagawa, Yuichi Shibuya, Takashi Kojima, Yasushi Toh, Morihito Okada, Shuichi Hironaka, Yuji Akiyama, Yoshito Komatsu, Kazuhiro Maejima, Hidewaki Nakagawa, Ritsuko Onuki, Momoko Nagai, Mamoru Kato, Keisuke Kanato, Aya Kuchiba, Kenichi Nakamura, Yuko Kitagawa
Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1. Cancer science 113 (3) (2022)
Hanae Ida, Takafumi Koyama, Takaaki Mizuno, Kuniko Sunami, Takashi Kubo, Kazuki Sudo, Kayoko Tao, Makoto Hirata, Kan Yonemori, Ken Kato, Takuji Okusaka, Yuichiro Ohe, Yoshiyuki Matsui, Naoya Yamazaki, Chitose Ogawa, Akira Kawai, Yoshitaka Narita, Minoru Esaki, Noboru Yamamoto
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Cancer science (2022)
Kentaro Harada, Shun Yamamoto, Ken Kato
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan. Expert opinion on biological therapy 22 (11) (2022)
Lin Shen, Ken Kato, Sung-Bae Kim, Jaffer A Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Longzhen Zhang, Tienan Yi, Jong-Mu Sun, Jianhua Chen, Guohua Yu, Chen-Yuan Lin, Hiroki Hara, Qing Bi, Taroh Satoh, Roberto A Pazo-Cid, Hendrick-Tobias Arkenau, Christophe Borg, Florian Lordick, Liyun Li, Ningning Ding, Aiyang Tao, Jingwen Shi, Eric Van Cutsem, null null
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (26) (2022)
Manish A Shah, Takashi Kojima, Daniel Hochhauser, Peter Enzinger, Judith Raimbourg, Antoine Hollebecque, Florian Lordick, Sung-Bae Kim, Masahiro Tajika, Albert Craig Lockhart, Hendrick-Tobias Arkenau, Farid El-Hajbi, Mukul Gupta, Per Pfeiffer, Pooja Bhagia, Zhu Alexander Cao, Jared Lunceford, Shailaja Suryawanshi, Mark Ayers, Matthew J Marton, Ken Kato
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future oncology (London, England) (2022)
Kentaro Harada, Shun Yamamoto, Ken Kato
Pembrolizumab for the treatment of advanced esophageal cancer. Future oncology (London, England) 18 (18) (2022)
Kuno Suzuki, Tatsuya Yamaguchi, Masakazu Kohda, Masami Tanaka, Hiroyuki Takemura, Mitsuru Wakita, Yoko Tabe, Shunsuke Kato, Motomi Nasu, Takashi Hashimoto, Shinji Mine, Nobuko Serizawa, Ko Tomishima, Akihito Nagahara, Takahisa Matsuda, Taiki Yamaji, Shoichiro Tsugane, Yutaka Saito, Hiroyuki Daiko, Takaki Yoshikawa, Ken Kato, Takuji Okusaka, Takahiro Ochiya, Yusuke Yamamoto, Shoji Yotsui, Takashi Yamamoto, Tomoyuki Yamasaki, Hiroshi Miyata, Masayoshi Yasui, Takeshi Omori, Kazuyoshi Ohkawa, Kenji Ikezawa, Tasuku Nakabori, Naotoshi Sugimoto, Toshihiro Kudo, Keiichi Yoshida, Masayuki Ohue, Takashi Nishizawa
Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples. PloS one 17 (12) (2022)
Chihiro Udagawa, Mari Hara Nakano, Teruhiko Yoshida, Yuichiro Ohe, Ken Kato, Taisei Mushiroda, Hitoshi Zembutsu
Association between genetic variants and the risk of nivolumab-induced immune-related adverse events. Pharmacogenomics 23 (16) (2022)
Kuno Suzuki, Tatsuya Yamaguchi, Masakazu Kohda, Masami Tanaka, Hiroyuki Takemura, Mitsuru Wakita, Yoko Tabe, Shunsuke Kato, Motomi Nasu, Takashi Hashimoto, Shinji Mine, Nobuko Serizawa, Ko Tomishima, Akihito Nagahara, Takahisa Matsuda, Taiki Yamaji, Shoichiro Tsugane, Yutaka Saito, Hiroyuki Daiko, Takaki Yoshikawa, Ken Kato, Takuji Okusaka, Takahiro Ochiya, Yusuke Yamamoto, Shoji Yotsui, Takashi Yamamoto, Tomoyuki Yamasaki, Hiroshi Miyata, Masayoshi Yasui, Takeshi Omori, Kazuyoshi Ohkawa, Kenji Ikezawa, Tasuku Nakabori, Naotoshi Sugimoto, Toshihiro Kudo, Keiichi Yoshida, Masayuki Ohue, Takashi Nishizawa
Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples. PloS one 17 (12) (2022)
Kaori Hino, Tomohiro Nishina, Takeshi Kajiwara, Hideaki Bando, Maho Nakamura, Shigenori Kadowaki, Keiko Minashi, Satoshi Yuki, Takashi Ohta, Hiroki Hara, Takuro Mizukami, Toshikazu Moriwaki, Koushiro Ohtsubo, Masato Komoda, Seiichiro Mitani, Fumio Nagashima, Ken Kato, Takanobu Yamada, Hiroko Hasegawa, Kentaro Yamazaki, Takayuki Yoshino, Ichinosuke Hyodo
Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric Cancer. JCO precision oncology 6 (2022)
Ken Kato, Yuichiro Doki, Takashi Ogata, Satoru Motoyama, Hisato Kawakami, Masaki Ueno, Takashi Kojima, Yasuhiro Shirakawa, Morihito Okada, Ryu Ishihara, Yutaro Kubota, Carlos Amaya-Chanaga, Tian Chen, Yasuhiro Matsumura, Yuko Kitagawa
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). Esophagus : official journal of the Japan Esophageal Society (2022)
Yoshiaki Nakamura, Wataru Okamoto, Tadamichi Denda, Tomohiro Nishina, Yoshito Komatsu, Satoshi Yuki, Hisateru Yasui, Taito Esaki, Yu Sunakawa, Makoto Ueno, Eiji Shinozaki, Nobuhisa Matsuhashi, Takashi Ohta, Ken Kato, Koushiro Ohtsubo, Hideaki Bando, Hiroki Hara, Taroh Satoh, Kentaro Yamazaki, Yoshiyuki Yamamoto, Naohiro Okano, Tetsuji Terazawa, Takeshi Kato, Eiji Oki, Akihito Tsuji, Yosuke Horita, Yasuo Hamamoto, Akihito Kawazoe, Hiromichi Nakajima, Shogo Nomura, Ryuta Mitani, Mihoko Yuasa, Kiwamu Akagi, Takayuki Yoshino
Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. JCO precision oncology 6 (2022)
Toru Kadono, Shun Yamamoto, Ken Kato
Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. Japanese journal of clinical oncology 52 (10) (2022)
Kuno Suzuki, Tatsuya Yamaguchi, Masakazu Kohda, Masami Tanaka, Hiroyuki Takemura, Mitsuru Wakita, Yoko Tabe, Shunsuke Kato, Motomi Nasu, Takashi Hashimoto, Shinji Mine, Nobuko Serizawa, Ko Tomishima, Akihito Nagahara, Takahisa Matsuda, Taiki Yamaji, Shoichiro Tsugane, Yutaka Saito, Hiroyuki Daiko, Takaki Yoshikawa, Ken Kato, Takuji Okusaka, Takahiro Ochiya, Yusuke Yamamoto, Shoji Yotsui, Takashi Yamamoto, Tomoyuki Yamasaki, Hiroshi Miyata, Masayoshi Yasui, Takeshi Omori, Kazuyoshi Ohkawa, Kenji Ikezawa, Tasuku Nakabori, Naotoshi Sugimoto, Toshihiro Kudo, Keiichi Yoshida, Masayuki Ohue, Takashi Nishizawa
Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples. PloS one 17 (12) (2022)
Toru Kadono, Shun Yamamoto, Toshiharu Hirose, Go Ikeda, Akihiro Ohara, Mai Itoyama, Kazuki Yokoyama, Yoshitaka Honma, Taiki Hashimoto, Shigeki Sekine, Koshiro Ishiyama, Junya Oguma, Hiroyuki Daiko, Ken Kato
Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. Esophagus : official journal of the Japan Esophageal Society (2022)
Kensei Yamaguchi, Keiko Minashi, Daisuke Sakai, Tomohiro Nishina, Yasushi Omuro, Masahiro Tsuda, Shiroh Iwagami, Hiasto Kawakami, Taito Esaki, Naotoshi Sugimoto, Takashi Oshima, Ken Kato, Kenji Amagai, Hisashi Hosaka, Keigo Komine, Hisateru Yasui, Yuji Negoro, Kenji Ishido, Takahiro Tsushima, Shirong Han, Shinichi Shiratori, Tomoko Takami, Kohei Shitara
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer. Cancer science 113 (8) (2022)
Kuno Suzuki, Tatsuya Yamaguchi, Masakazu Kohda, Masami Tanaka, Hiroyuki Takemura, Mitsuru Wakita, Yoko Tabe, Shunsuke Kato, Motomi Nasu, Takashi Hashimoto, Shinji Mine, Nobuko Serizawa, Ko Tomishima, Akihito Nagahara, Takahisa Matsuda, Taiki Yamaji, Shoichiro Tsugane, Yutaka Saito, Hiroyuki Daiko, Takaki Yoshikawa, Ken Kato, Takuji Okusaka, Takahiro Ochiya, Yusuke Yamamoto, Shoji Yotsui, Takashi Yamamoto, Tomoyuki Yamasaki, Hiroshi Miyata, Masayoshi Yasui, Takeshi Omori, Kazuyoshi Ohkawa, Kenji Ikezawa, Tasuku Nakabori, Naotoshi Sugimoto, Toshihiro Kudo, Keiichi Yoshida, Masayuki Ohue, Takashi Nishizawa
Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples. PloS one 17 (12) (2022)
Kuno Suzuki, Tatsuya Yamaguchi, Masakazu Kohda, Masami Tanaka, Hiroyuki Takemura, Mitsuru Wakita, Yoko Tabe, Shunsuke Kato, Motomi Nasu, Takashi Hashimoto, Shinji Mine, Nobuko Serizawa, Ko Tomishima, Akihito Nagahara, Takahisa Matsuda, Taiki Yamaji, Shoichiro Tsugane, Yutaka Saito, Hiroyuki Daiko, Takaki Yoshikawa, Ken Kato, Takuji Okusaka, Takahiro Ochiya, Yusuke Yamamoto, Shoji Yotsui, Takashi Yamamoto, Tomoyuki Yamasaki, Hiroshi Miyata, Masayoshi Yasui, Takeshi Omori, Kazuyoshi Ohkawa, Kenji Ikezawa, Tasuku Nakabori, Naotoshi Sugimoto, Toshihiro Kudo, Keiichi Yoshida, Masayuki Ohue, Takashi Nishizawa
Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples. PloS one 17 (12) (2022)
Masashi Ishikawa, Atsuo Takashima, Yusuke Nagata, Ryoichi Sawada, Masahiko Aoki, Hiroshi Imazeki, Hidekazu Hirano, Hirokazu Shoji, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Ken Kato, Masayuki Saruta, Narikazu Boku
Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study. PloS one 16 (9) (2021)
Go Ikeda, Shun Yamamoto, Ken Kato
The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy. Expert opinion on drug safety (2021)
Manish A Shah, Jaafar Bennouna, Toshihiko Doi, Lin Shen, Ken Kato, Antoine Adenis, Harvey J Mamon, Markus Moehler, Xiaolong Fu, Byoung Chul Cho, Sonal Bordia, Pooja Bhagia, Chie-Schin Shih, Anjali Desai, Peter Enzinger
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future oncology (London, England) 17 (10) (2021)
Yoshiaki Nakamura, Wataru Okamoto, Takeshi Kato, Taito Esaki, Ken Kato, Yoshito Komatsu, Satoshi Yuki, Toshiki Masuishi, Tomohiro Nishina, Hiromichi Ebi, Kentaro Sawada, Hiroya Taniguchi, Nozomu Fuse, Shogo Nomura, Makoto Fukui, Seiko Matsuda, Yasutoshi Sakamoto, Hiroshi Uchigata, Kana Kitajima, Naomi Kuramoto, Takashi Asakawa, Steve Olsen, Justin I Odegaard, Akihiro Sato, Satoshi Fujii, Atsushi Ohtsu, Takayuki Yoshino
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nature medicine 27 (11) (2021)
Toshiharu Hirose, Shun Yamamoto, Ken Kato
Emerging data on nivolumab for esophageal squamous cell carcinoma. Expert review of gastroenterology & hepatology 15 (8) (2021)
Shun Yamamoto, Ken Kato
Immuno-oncology for esophageal cancer. Future oncology (London, England) 16 (32) (2020)
Takashi Kojima, Manish A Shah, Kei Muro, Eric Francois, Antoine Adenis, Chih-Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung-Bae Kim, Se-Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter Enzinger, Shu-Kui Qin, Paula Ferreira, Jia Chen, Gustavo C Girotto, Christelle De La Fouchardière, Helene Senellart, Raed Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, S Peter Kang, Jean-Philippe Metges, null null
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (35) (2020)
Keisuke Asakura, Tsukasa Kadota, Juntaro Matsuzaki, Yukihiro Yoshida, Yusuke Yamamoto, Kazuo Nakagawa, Satoko Takizawa, Yoshiaki Aoki, Eiji Nakamura, Junichiro Miura, Hiromi Sakamoto, Ken Kato, Shun-Ichi Watanabe, Takahiro Ochiya
A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy. Communications biology 3 (1) (2020)
Yukihiro Nakatani, Ken Kato, Hirokazu Shoji, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Toshikazu Ushijima, Yoshinori Ito, Jun Itami, Narikazu Boku
Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer. International journal of clinical oncology 25 (6) (2020)
Yoshiaki Nakamura, Hiroya Taniguchi, Masafumi Ikeda, Hideaki Bando, Ken Kato, Chigusa Morizane, Taito Esaki, Yoshito Komatsu, Yasuyuki Kawamoto, Naoki Takahashi, Makoto Ueno, Yoshinori Kagawa, Tomohiro Nishina, Takeshi Kato, Yoshiyuki Yamamoto, Junji Furuse, Tadamichi Denda, Hiasto Kawakami, Eiji Oki, Takako Nakajima, Naohiro Nishida, Kensei Yamaguchi, Hisateru Yasui, Masahiro Goto, Nobuhisa Matsuhashi, Koushiro Ohtsubo, Kentaro Yamazaki, Akihito Tsuji, Wataru Okamoto, Katsuya Tsuchihara, Takeharu Yamanaka, Izumi Miki, Yasutoshi Sakamoto, Hiroko Ichiki, Masayuki Hata, Riu Yamashita, Atsushi Ohtsu, Justin I Odegaard, Takayuki Yoshino
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nature medicine 26 (12) (2020)
Koya Fukunaga, Eiji Hishinuma, Masahiro Hiratsuka, Ken Kato, Takuji Okusaka, Takeo Saito, Kyung Sue Hong, Teruhiko Yoshida, Hitoshi Zembutsu, Masashi Ikeda, Taisei Mushiroda
Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population. Journal of human genetics 66 (2) (2020)
Ken Kato, Yuichiro Doki, Takashi Ura, Yasuo Hamamoto, Takashi Kojima, Takahiro Tsushima, Shuichi Hironaka, Hiroki Hara, Toshihiro Kudo, Satoru Iwasa, Kei Muro, Hirofumi Yasui, Keiko Minashi, Kensei Yamaguchi, Atsushi Ohtsu, Yuko Kitagawa
Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer science 111 (5) (2020)
Shun Yamamoto, Ken Kato, Hiroyuki Daiko, Takashi Kojima, Hiroki Hara, Tetsuya Abe, Yasuhiro Tsubosa, Kengo Nagashima, Kazunori Aoki, Yukihiro Mizoguchi, Shigehisa Kitano, Shinichi Yachida, Satoshi Shiba, Yuko Kitagawa
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future oncology (London, England) 16 (19) (2020)
Satoko Monma, Ken Kato, Hirokazu Shouji, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Satoru Iwasa, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, Narikazu Boku, Kengo Nagashima, Yoshinori Ito, Jun Itami
Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer. Esophagus : official journal of the Japan Esophageal Society 16 (4) (2019)
Naofumi Asano, Juntaro Matsuzaki, Makiko Ichikawa, Junpei Kawauchi, Satoko Takizawa, Yoshiaki Aoki, Hiromi Sakamoto, Akihiko Yoshida, Eisuke Kobayashi, Yoshikazu Tanzawa, Robert Nakayama, Hideo Morioka, Morio Matsumoto, Masaya Nakamura, Tadashi Kondo, Ken Kato, Naoto Tsuchiya, Akira Kawai, Takahiro Ochiya
A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes. Nature communications 10 (1) (2019)
Fumihiko Urabe, Juntaro Matsuzaki, Yusuke Yamamoto, Takahiro Kimura, Tomohiko Hara, Makiko Ichikawa, Satoko Takizawa, Yoshiaki Aoki, Shumpei Niida, Hiromi Sakamoto, Ken Kato, Shin Egawa, Hiroyuki Fujimoto, Takahiro Ochiya
Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (10) (2019)
Ken Kato, Takashi Ura, Wasaburo Koizumi, Satoru Iwasa, Chikatoshi Katada, Mizutomo Azuma, Satoshi Ishikura, Yoshinori Nakao, Hiroshi Onuma, Kei Muro
Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study. Cancer science 109 (3) (2018)
Sho Shiino, Juntaro Matsuzaki, Akihiko Shimomura, Junpei Kawauchi, Satoko Takizawa, Hiromi Sakamoto, Yoshiaki Aoki, Masayuki Yoshida, Kenji Tamura, Ken Kato, Takayuki Kinoshita, Yuko Kitagawa, Takahiro Ochiya
Serum miRNA-based Prediction of Axillary Lymph Node Metastasis in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (6) (2018)
Akira Yokoi, Juntaro Matsuzaki, Yusuke Yamamoto, Yutaka Yoneoka, Kenta Takahashi, Hanako Shimizu, Takashi Uehara, Mitsuya Ishikawa, Shun-Ichi Ikeda, Takumi Sonoda, Junpei Kawauchi, Satoko Takizawa, Yoshiaki Aoki, Shumpei Niida, Hiromi Sakamoto, Ken Kato, Tomoyasu Kato, Takahiro Ochiya
Integrated extracellular microRNA profiling for ovarian cancer screening. Nature communications 9 (1) (2018)